Dermatologlar, rolü korumalıdır, ημιατρική θεραπεία του καρκίνου των κυττάρων του δέρματος

Shannon C. Trotter, DO, FAOCD, a certified dermatologist at Dermatologists of the Central States in Ohio, discusses immunotherapy options for advanced cutaneous squamous cell carcinoma (cSCC) and why dermatologists should remain involved in the care process even after patients are referred to oncology. In an interview with HCPLive, Trotter highlights the importance of dermatologists’ active role in the care process for patients living with locally advanced or metastatic cSCC, as well as the expected Medicare cuts for advanced cSCC and the future of artificial intelligence in skin cancer care. Trotter and Todd E. Schlesinger, MD, co-presented a session titled “Seminar-In-Depth: Deep Dive on Cutaneous Squamous Cell Carcinoma and the Latest in Immunotherapy” at the Fall Clinical Dermatology Conference in Las Vegas, Nevada, on October 10.[^1] Trotter noted that approximately 95% of cSCC cases are treatable, but that approximately 5% become more challenging to manage. She highlighted three approved immune checkpoint inhibitors for locally advanced or metastatic cSCC: pembrolizumab (Keytruda), cemiplimab (Libtayo), and cosibelimab (Unloxcyt). Research into the formulations to be injected, particularly with cemiplimab, could play a role for dermatologists in the clinic setting as well. “They may seem far away from dermatologists, but in reality, we are the quarterback in skin cancer. Whether it’s on the skin or palpating a lymph node, we may be the first to detect it. Therefore, even if our patients are referred to oncology, we need to remain involved in the care process,” Trotter said.

Trotter also evaluated the anticipated Medicare cuts in terms of patient access. Older adults who are more affected by squamous cell carcinoma may experience delays in diagnosis and treatment. With early detection, survival rates for melanoma are approximately 100%; Trotter added that the dermatology community has called for a petition against the cuts. Looking ahead, Trotter highlighted augmented intelligence, which combines artificial intelligence with physician reasoning, as a significant opportunity in both melanoma and non-melanoma squamous cell carcinoma. New diagnostic tools may enable earlier detection. Genomic profiling can provide prognostic information, either alone or in conjunction with artificial intelligence, and may guide treatment decisions in the future. [^1]: Schlesinger TE, Trotter SC. Seminar-in-depth: deep dive on cutaneous squamous cell carcinoma and the latest in immunotherapy. Presentation: 2026 Fall Clinical Dermatology Conference; October 8-11, 2026; Las Vegas, NV.

💬 Community Masası & Tartışma

Bu gelişme hakkında düşüncelerinizi, donanım deneyimlerinizi veya sorularınızı Community Forumumuzda paylaşın.

Foruma Katıl & Yanıtla ➔